SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today reviewed its 2006 progress, announced corporate goals for 2007, and announced its decision to discontinue development of IPdR (ropidoxuridine).
